Alkermes (ALKS) Total Non-Current Liabilities (2011 - 2026)
Alkermes' (ALKS) quarterly Total Non-Current Liabilities came in at $2.4 billion in Q1 2026, up 368.59% year-on-year from $511.5 million in Q1 2025, and up 259.0% on a QoQ basis from $667.7 million in Q4 2025.
Alkermes (ALKS) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Total Non-Current Liabilities data on file, last reported at $2.4 billion in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 368.59% year-over-year to $2.4 billion in Q1 2026; TTM through Mar 2026 was $2.4 billion, a 368.59% increase from a year earlier, with the FY2025 full-year figure at $667.7 million, up 24.9% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $2.4 billion, up from $667.7 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ALKS reached as high as $2.4 billion in Q1 2026 and fell as low as $511.5 million in Q1 2025.
- Historically, Total Non-Current Liabilities has averaged $860.6 million across 5 years, with a median of $856.2 million in 2022.
- Across the five-year window, Total Non-Current Liabilities sank 39.5% in 2024 and soared 368.59% in 2026, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $877.8 million in 2022, then rose by 0.66% to $883.7 million in 2023, then sank by 39.5% to $534.6 million in 2024, then grew by 24.9% to $667.7 million in 2025, then surged by 259.0% to $2.4 billion in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $2.4 billion in Q1 2026, $667.7 million in Q4 2025, and $539.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 2.40 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.40 Bn |
| Dec 31, 2025 | 667.70 Mn |
| Sep 30, 2025 | 539.33 Mn |
| Jun 30, 2025 | 572.18 Mn |
| Mar 31, 2025 | 511.54 Mn |
| Dec 31, 2024 | 534.57 Mn |
| Sep 30, 2024 | 810.56 Mn |
| Jun 30, 2024 | 874.54 Mn |
| Mar 31, 2024 | 820.17 Mn |
| Dec 31, 2023 | 883.66 Mn |
| Sep 30, 2023 | 870.03 Mn |
| Jun 30, 2023 | 858.53 Mn |
| Mar 31, 2023 | 868.66 Mn |
| Dec 31, 2022 | 877.84 Mn |
| Sep 30, 2022 | 856.19 Mn |
| Jun 30, 2022 | 829.89 Mn |
| Mar 31, 2022 | 858.55 Mn |
| Dec 31, 2021 | 868.25 Mn |
| Sep 30, 2021 | 867.15 Mn |
| Jun 30, 2021 | 803.34 Mn |